{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:25:25Z","timestamp":1770823525858,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2019,5]]},"abstract":"Background and Objectives<\/jats:title>Fetal RHD<\/jats:styled-content><\/jats:italic> genotyping of cell\u2010free fetal DNA<\/jats:styled-content> from RhD\u2010negative pregnant women can be used to guide targeted antenatal and postnatal anti\u2010D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories.<\/jats:p><\/jats:sec>Materials and Methods<\/jats:title>Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD<\/jats:styled-content><\/jats:italic>, verified by pre\u2010workshop testing using quantitative real\u2010time PCR<\/jats:styled-content> (qPCR<\/jats:styled-content>) analysis of RHD<\/jats:styled-content><\/jats:italic> exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR<\/jats:styled-content> with a total of eight different combinations of RHD<\/jats:styled-content><\/jats:italic> exon targets. The samples were tested blindly.<\/jats:p><\/jats:sec>Results<\/jats:title>Fetal RHD<\/jats:styled-content><\/jats:italic> genotyping was performed with no false\u2010negative and no false\u2010positive results. One inconclusive result was reported for the RHD<\/jats:styled-content><\/jats:italic>\u2010positive sample, and four inconclusive results were reported for the RHD<\/jats:styled-content><\/jats:italic>\u2010negative sample. All clinical conclusions were satisfactory.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD<\/jats:styled-content><\/jats:italic> genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12768","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T03:07:32Z","timestamp":1551755252000},"page":"386-393","source":"Crossref","is-referenced-by-count":19,"title":["Noninvasive fetal RHD<\/scp><\/i> genotyping to guide targeted anti\u2010D prophylaxis\u2013an external quality assessment workshop"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2487-5373","authenticated-orcid":false,"given":"Frederik Banch","family":"Clausen","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Obstetrics and Gynaecology Yong Loo Lin School of Medicine National University of Singapore Singapore City Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Natalie","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Obstetrics and Gynaecology Yong Loo Lin School of Medicine National University of Singapore Singapore City Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Noninvasive Fetal RHD Genotyping EQA2017 Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12099"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12265"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030711"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta22130"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812103392402"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60534-X"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000379"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-14-87"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03362.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4419"},{"key":"e_1_2_9_12_1","first-page":"1","article-title":"Sensitivity of fetal RHD screening for safe guidance of targeted anti\u2010D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands","volume":"355","author":"Haas M","year":"2016","journal-title":"BMJ"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13191"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2018.1475681"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12616"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12615"},{"issue":"1","key":"e_1_2_9_17_1","first-page":"39","article-title":"Non\u2010invasive fetal RHD screening allows discontinuation of newborn RhD testing. 35th International Congress of the ISBT, Toronto, Canada, June 2\u20136, 2018","volume":"113","author":"Kuosmanen M","year":"2018","journal-title":"Vox Sang"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076990"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000216580"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12405"},{"key":"e_1_2_9_21_1","first-page":"359","article-title":"Non\u2010invasive foetal RhD genotyping to guide anti\u2010D prophylaxis: an external quality assurance workshop","volume":"16","author":"Clausen FB","year":"2018","journal-title":"Blood Transfus"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4468"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32834bab2d"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.12768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:13:01Z","timestamp":1694365981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/vox.12768"],"URL":"https:\/\/doi.org\/10.1111\/vox.12768","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]}}}